Brevan Howard Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Brevan Howard Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.6M	Buy	155,727 +74,157	+91%	+$5.19M	0.09%	152
2026 Q1	$6.06M	Sell	81,570 -91,953	-53%	-$6.67M	0.05%	199
2025 Q4	$13.2M	Buy	173,523 +121,105	+231%	+$7.95M	0.14%	90
2025 Q3	$2.72M	Sell	52,418 -51,692	-50%	-$2.52M	0.01%	439
2025 Q2	$4.5M	Buy	+104,110	New	+$3.79M	0.03%	402
2025 Q1	–	Sell	-14,760	Closed	-$405K	–	1164
2024 Q4	$405K	Sell	14,760 -9,722	-40%	-$251K	﹤0.01%	682
2024 Q3	$623K	Buy	24,482 +11,297	+86%	+$297K	﹤0.01%	621
2024 Q2	$334K	Buy	+13,185	New	+$360K	﹤0.01%	738

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Brevan Howard Capital Management's BBIO Position: Q2 2026 in Review

Brevan Howard Capital Management increased its BridgeBio Pharma (BBIO) stake by 91% in Q2 2026, buying an estimated $5.19M and bringing the position to 155,727 shares worth $11.6M. The position accounts for 0.09% of the portfolio, ranked #152.

Brevan Howard Capital Management first reported a position in BBIO in Q2 2024 and has held it in 8 quarters since. The position peaked at $13.2M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Brevan Howard Capital Management held 155,727 shares of BridgeBio Pharma worth $11.6M as of Q2 2026.
Brevan Howard Capital Management bought 74,157 BridgeBio Pharma shares in Q2 2026, an estimated $5.19M.
BridgeBio Pharma made up 0.09% of Brevan Howard Capital Management's portfolio in Q2 2026, its #152 holding.
Brevan Howard Capital Management first reported a position in BridgeBio Pharma in Q2 2024 and has held it in 8 quarters since.
Brevan Howard Capital Management's BridgeBio Pharma position peaked at $13.2M in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.